The Digital Diabetes Patient Reminder (DIPAR) Tool to Improve Clinical Outcomes and Process of Management in Adults With Type 2 Diabetes: A Proof-of-Concept Randomized Controlled Trial
Digital health tools may present an opportunity to address these challenges by enhancing care delivery, improving patient engagement, and facilitating better disease management for chronic diseases such as type 2 diabetes mellitus (T2DM). This primary objective of this randomized controlled trial is to evaluate whether the Diabetes Digital Patient Reminder (DIPAR), embedded in patient portal, can increase the proportion of T2DM patients who have their albuminuria measured at least once annually by either a general practitioner (GP) or a diabetes specialist, as documented in their hospital medical records (EMD), thereby reflecting active monitoring of diabetes-related parameters.
• Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures;
• Adults 18 years or older;
• Treated and followed-up for Type 2 diabetes at the department of endocrinology at the participating hospitals;
• Patients with (the ability to access) the MyNexuz patient portal;
• Patients with the ability to understand Dutch, French or English.